Actavis
In 2013 Actavis acquired Warner Chilcott, creating an $11 billion specialty pharmaceutical company with over $3 billion in pro forma sales. The combination capitalises on the complementary specialty pharmaceuticals strengths and market positions of the two organisations, building a leader in women’s health and urology, as well as a company with important positions in gastroenterology and dermatology.
Financial Data
-
31st Dec 14 Source: CRO
- €12.1 billion turnover
- 2,800 employees
-
31st Dec 12 Source: CRO
- €1.9 billion turnover
-
€304.9 million
profit - 2,789 employees
- 3 more years available »
Ranking
By Turnover
(€12.1 billion)- 7th in Top Companies
- 1st in Pharma
- 3rd in Manufacturing
By Employees
(2,800)- 68th in Top Companies
- 6th in Pharma
- 10th in Manufacturing
-
- 2,800
- €12.1 billion
Employees
- Tony Hynds CEO/Managing Director